Cargando…

Recombinant adeno-associated virus-based gene therapy combined with tissue engineering for musculoskeletal regenerative medicine

Recombinant adeno-associated viral (rAAV) vector-mediated gene delivery is a novel molecular therapeutic approach for musculoskeletal disorders which achieves tissue regeneration by delivering a transgene to the impaired tissue. In recent years, substantial scientific progress in rAAV gene therapy h...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yiqing, Chu, Xiangyu, Wang, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Medical Multimedia Press Co., Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255831/
https://www.ncbi.nlm.nih.gov/pubmed/35837257
http://dx.doi.org/10.3877/cma.j.issn.2096-112X.2021.01.004
_version_ 1784741003146559488
author Wang, Yiqing
Chu, Xiangyu
Wang, Bing
author_facet Wang, Yiqing
Chu, Xiangyu
Wang, Bing
author_sort Wang, Yiqing
collection PubMed
description Recombinant adeno-associated viral (rAAV) vector-mediated gene delivery is a novel molecular therapeutic approach for musculoskeletal disorders which achieves tissue regeneration by delivering a transgene to the impaired tissue. In recent years, substantial scientific progress in rAAV gene therapy has led to several clinical trials for human musculoskeletal diseases. Nevertheless, there are still limitations in developing an optimal gene therapy model due to the low transduction efficiency and fast degradation of the gene vectors. To overcome the challenges of rAAV gene therapy, tissue engineering combined with gene therapy has emerged as a more promising alternative. An rAAV viral vector incorporated into a biomaterial has a more controlled gene expression, lower immune response, and higher efficiency. A number of biomaterials and architectures have been combined with rAAV viral vectors, each having its own advantages and limitations. This review aims to give a broad introduction to combinatorial therapy and the recent progress this new technology has offered.
format Online
Article
Text
id pubmed-9255831
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Chinese Medical Multimedia Press Co., Ltd
record_format MEDLINE/PubMed
spelling pubmed-92558312022-07-13 Recombinant adeno-associated virus-based gene therapy combined with tissue engineering for musculoskeletal regenerative medicine Wang, Yiqing Chu, Xiangyu Wang, Bing Biomater Transl Review Recombinant adeno-associated viral (rAAV) vector-mediated gene delivery is a novel molecular therapeutic approach for musculoskeletal disorders which achieves tissue regeneration by delivering a transgene to the impaired tissue. In recent years, substantial scientific progress in rAAV gene therapy has led to several clinical trials for human musculoskeletal diseases. Nevertheless, there are still limitations in developing an optimal gene therapy model due to the low transduction efficiency and fast degradation of the gene vectors. To overcome the challenges of rAAV gene therapy, tissue engineering combined with gene therapy has emerged as a more promising alternative. An rAAV viral vector incorporated into a biomaterial has a more controlled gene expression, lower immune response, and higher efficiency. A number of biomaterials and architectures have been combined with rAAV viral vectors, each having its own advantages and limitations. This review aims to give a broad introduction to combinatorial therapy and the recent progress this new technology has offered. Chinese Medical Multimedia Press Co., Ltd 2021-03-28 /pmc/articles/PMC9255831/ /pubmed/35837257 http://dx.doi.org/10.3877/cma.j.issn.2096-112X.2021.01.004 Text en https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review
Wang, Yiqing
Chu, Xiangyu
Wang, Bing
Recombinant adeno-associated virus-based gene therapy combined with tissue engineering for musculoskeletal regenerative medicine
title Recombinant adeno-associated virus-based gene therapy combined with tissue engineering for musculoskeletal regenerative medicine
title_full Recombinant adeno-associated virus-based gene therapy combined with tissue engineering for musculoskeletal regenerative medicine
title_fullStr Recombinant adeno-associated virus-based gene therapy combined with tissue engineering for musculoskeletal regenerative medicine
title_full_unstemmed Recombinant adeno-associated virus-based gene therapy combined with tissue engineering for musculoskeletal regenerative medicine
title_short Recombinant adeno-associated virus-based gene therapy combined with tissue engineering for musculoskeletal regenerative medicine
title_sort recombinant adeno-associated virus-based gene therapy combined with tissue engineering for musculoskeletal regenerative medicine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255831/
https://www.ncbi.nlm.nih.gov/pubmed/35837257
http://dx.doi.org/10.3877/cma.j.issn.2096-112X.2021.01.004
work_keys_str_mv AT wangyiqing recombinantadenoassociatedvirusbasedgenetherapycombinedwithtissueengineeringformusculoskeletalregenerativemedicine
AT chuxiangyu recombinantadenoassociatedvirusbasedgenetherapycombinedwithtissueengineeringformusculoskeletalregenerativemedicine
AT wangbing recombinantadenoassociatedvirusbasedgenetherapycombinedwithtissueengineeringformusculoskeletalregenerativemedicine